| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (NCT05357482) | National Heart, Lung, and Blood Institute (NHLBI) | 2022-05-12 |
| Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) (NCT05356195) | Vertex Pharmaceuticals Incorporated | 2022-05-03 |
| The Prevelence of IVS 1-6 (T-C) [HBB:c.92 +6 T-C] Gene Mutation in Suspected Cases of β Thalassemia in Assiut University Hospitals (NCT05370677) | Assiut University | 2022-05-01 |
| Long Term Beta Thalassemia Treatment: Findings From The Extension Period (NCT06490601) | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 2022-04-01 |
| Assessment of Cognitive Function, Fatigue and Health Related Quality of Life in Children With Beta Thalassemia (NCT05469230) | Cairo University | 2022-01-15 |
| Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia (NCT04938635) | Vifor (International) Inc. | 2021-09-20 |
| Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study. (NCT06239389) | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 2021-09-01 |
| Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) (NCT04973280) | Celgene | 2021-07-26 |
| Vitamin E Supplementation for Children With Transfusion Dependent Beta Thalassemia on Different Iron Chelation Regimen (NCT06509581) | Ain Shams University | 2021-07-05 |
| Iron Status in BTM With Blood Transfusion (NCT04947540) | Assiut University | 2021-07-01 |
| Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram (NCT04929574) | Nanfang Hospital, Southern Medical University | 2021-07-01 |
| Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP) (NCT04247750) | Università degli Studi di Ferrara | 2021-04-13 |
| AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion (NCT04099966) | Mitchell Cairo | 2021-04-01 |
| A Long-term Follow-up Study in Participants Who Received CTX001 (NCT04208529) | Vertex Pharmaceuticals Incorporated | 2021-01-20 |
| SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias (NCT03801889) | Abfero Pharmaceuticals, Inc | 2020-08-01 |
| Complications in Children With B- Thalassemia Major (NCT03462784) | Assiut University | 2020-08-01 |
| Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia (NCT04364269) | Vifor (International) Inc. | 2020-06-11 |
| ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19 (NCT06831799) | Hospital Universitari Vall d'Hebron Research Institute | 2020-04-15 |
| Association of Hb F Level With Clinical Severity of Beta Thalassemia (NCT04917978) | Nanfang Hospital, Southern Medical University | 2019-12-01 |
| Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia (NCT04143724) | Celgene | 2019-11-07 |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (NCT04064060) | Celgene | 2019-08-12 |
| Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (NCT03877809) | Rare Partners srl Impresa Sociale | 2019-06-27 |
| Choroidal Thickness in Beta-thalassemia Patients (NCT04067258) | University Hospital of Patras | 2019-05-01 |
| Detection Of β-thalassemia Carriers In Assiut (NCT03822585) | Assiut University | 2019-03-01 |
| Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin (NCT03889977) | University of Thessaly | 2019-02-11 |
| the Efficacy and Safety of Sugammadex in Children 0-2 Years Old (NCT03728543) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2018-11-15 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia (NCT03655678) | Vertex Pharmaceuticals Incorporated | 2018-09-14 |
| Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector (NCT03351829) | Shenzhen Geno-Immune Medical Institute | 2017-12-01 |
| A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia (NCT03381833) | La Jolla Pharmaceutical Company | 2017-11-30 |
| A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia (NCT03271541) | Hoffmann-La Roche | 2017-10-26 |
| Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus (NCT03961828) | Tanta University | 2017-10-01 |
| A Study of EPEG in Beta Thalassemia Patients (NCT02950857) | Prolong Pharmaceuticals | 2017-06-28 |
| A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia (NCT03207009) | Genetix Biotherapeutics Inc. | 2017-06-08 |
| Genetic Variants Affecting the Clinical Severity of Beta Thalassemia (NCT04918056) | Nanfang Hospital, Southern Medical University | 2017-01-01 |
| A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype (NCT02906202) | Genetix Biotherapeutics Inc. | 2016-08-08 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (NCT02604433) | Celgene | 2016-05-02 |
| To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care (NCT02626689) | Celgene | 2016-03-01 |
| Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients (NCT02474420) | Kevin H.M. Kuo, MD, MSc, FRCPC | 2015-06-01 |
| Gene Therapy for Transfusion Dependent Beta-thalassemia (NCT02453477) | IRCCS San Raffaele | 2015-05-01 |
| Treatment of Iron Overload Requiring Chelation Therapy (NCT01927913) | Shire | 2014-11-20 |
| Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml) (NCT01996683) | Ain Shams University | 2014-11-01 |
| Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major (NCT02597595) | Tanta University | 2014-11-01 |
| Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia (NCT02274233) | Sideris Pharmaceuticals | 2014-10-01 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant (NCT01049854) | New York Medical College | 2011-09-01 |
| Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload (NCT01363908) | Shire | 2011-08-10 |
| Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major (NCT01206075) | University of Washington | 2010-10-01 |
| Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload (NCT01186419) | Shire | 2010-08-13 |
| Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients (NCT01016093) | Tehran University of Medical Sciences | 2009-11-01 |
| Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload (NCT01039636) | FerroKin BioSciences, Inc. | 2009-11-01 |
| Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia (NCT00790127) | HemaQuest Pharmaceuticals Inc. | 2009-03-01 |
| Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload (NCT00564941) | Novartis Pharmaceuticals | 2007-12-01 |
| Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment (NCT00447694) | Novartis | 2006-02-01 |
| Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases (NCT00115349) | Carelon Research | 2005-06-01 |
| Stem Cell Transplant in Sickle Cell Disease and Thalassemia (NCT00408447) | Columbia University | 2004-09-01 |
| Genetic Factors Affecting the Severity of Beta Thalassemia (NCT00159042) | Deborah Rund | 2004-07-01 |
| A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis (NCT00171171) | Novartis | 2004-05-01 |
| Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major (NCT00103753) | Royal Brompton & Harefield NHS Foundation Trust | 2004-05-01 |
| Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia (NCT00069862) | Genzyme, a Sanofi Company | 2003-09-01 |
| Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias (NCT00061763) | Novartis Pharmaceuticals | 2003-05-01 |
| Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions (NCT00061750) | Novartis Pharmaceuticals | 2003-05-01 |
| 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia (NCT00005934) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2000-06-01 |
| Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia) (NCT00001958) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1999-12-01 |
| Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia (NCT00006136) | Boston University | 1999-03-01 |
| Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia (NCT00029380) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-01-01 |
| Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone (NCT00000588) | Case Western Reserve University | 1989-06-05 |
| Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis (NCT00000595) | National Heart, Lung, and Blood Institute (NHLBI) | 1978-01-01 |
| Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia (NCT01092169) | Hillel Yaffe Medical Center | |